ArticleRheumatology and therapy2026
Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study.
Article in Rheumatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTreat-to-target strategies for rheumatoid arthritis (RA) aim for remission or low disease activity (LDA) and improve long-term outcomes. The objective of this analysis is to report early achievement of remission or LDA at 3 months (M) in a real-world RA population and explore the long-term (2 years) outcomes of achieving early remission/LDA.
methodsRA-BE-REAL is a 3-year, multinational, prospective, observational study of adult patients with RA. Patients initiated treatment with baricitinib (cohort A) or any biologic (b) disease-modifying anti-rheumatic drug (DMARD) or any other targeted synthetic (ts) (cohort B) for the first time. This analysis covers data from a European subpopulation of RA-BE-REAL. Effectiveness data at 3 months (early remission), and 24 months were presented descriptively. Logistic regression was used to determine associations between baseline characteristics and achievement of remission/LDA at 3 months and also associations between early remission/LDA and subsequent achievement of long-term remission/LDA at 24 months.
resultsAt 3 months, high proportions of patients in both cohorts (cohort A: 59.4%, cohort B: 49.3%) reached remission or LDA. Patients achieving early remission or LDA had greater improvement in short- and long-term pain, functioning (HAQ-DI), and quality of life (EQ-5D-5L) than those who did not. Logistic regression found that previous experience with ≥ 2 previous b/tsDMARDs, higher Clinical Disease Activity Index (CDAI) scores, and lower EQ-5D-5L scores at baseline were negative predictors for the achievement of early remission or LDA. Furthermore, achievement of remission or LDA at 3 months was associated with remission or LDA at 24 months.
conclusionsIn a routine clinical practice population, achieving early remission/LDA was associated with maintained remission/LDA at 2 years as well as long-term improvement in pain, physical function, and quality of life in both cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.